Getting to the Moon was the first chapter. Interlune and Astrolab are working on how to operate there.
Updated
March 6, 2026 1:32 AM
Apollo 17 Astronaut's Snapshot of Taurus-Littrow Valley. PHOTO: UNSPLASH
As plans for a long-term human presence on the Moon pick up pace, the focus is shifting from landing there to working there. It is one thing to reach the surface. It is another to build roads, prepare sites and extract materials in a way that can support real activity.
That is where Interlune and Astrolab come in. Interlune is a space resources company. Astrolab builds planetary rovers. The two are now working together to mount Interlune’s lunar digging system onto Astrolab’s Flexible Logistics and Exploration (FLEX) rover. They have completed a concept study and are planning hardware testing in Houston.
The aim is straightforward: combine a rover that can move reliably across the Moon with equipment that can dig, collect and handle lunar soil. Interlune is focused on harvesting natural resources from the Moon, starting with helium-3. To do that at scale, the system cannot sit in one place. It has to move across the surface, handle dust and operate in harsh conditions. "Reliable, autonomous mobility is crucial to the Interlune harvesting system and broader lunar infrastructure development", said Rob Meyerson, co-founder and CEO of Interlune. "Astrolab's FLEX is the right vehicle for the job".
By fitting its digging and collection hardware onto FLEX, Interlune is working toward a mobile system that can gather large amounts of lunar soil and support future construction needs. Beyond helium-3, the same setup could help prepare base sites, level ground, build protective barriers and lay the groundwork for other structures. In simple terms, it is about turning a rover into a working machine for the Moon.
The partnership also connects to Interlune’s work with Vermeer Corporation to develop equipment for continuous, high-volume digging adapted to lunar conditions. Taken together, the goal is to build systems that can support both commercial and government missions — whether that means resource extraction or preparing land for future bases.
For Astrolab, the collaboration strengthens the role of FLEX as more than just a transport vehicle.
"Working with Interlune further differentiates FLEX as the rover of choice for commercial and government Moon missions", said Jaret Matthews, Astrolab founder and CEO. "Interlune's expertise in developing and testing highly specialized regolith simulant will further enhance FLEX's ability to mitigate dust and operate in extreme environments".
Testing will be centered in Houston, which is becoming an important hub for commercial space development. Astrolab was the first company to lease space at the Texas A&M University Space Institute, currently under construction at NASA’s Johnson Space Center. Interlune operates the Houston-based Interlune Research Lab, where it creates and tests simulated versions of lunar soil.
That detail matters. Moon dust is fine, abrasive and difficult to manage. Before any hardware flies, it needs to prove it can survive and function in those conditions. By testing their systems in realistic soil simulants, the companies can refine how the rover moves and how the digging system performs.
The Houston lab is partially funded by the Texas Space Commission, reflecting the growing role of regional space initiatives in supporting private companies building beyond Earth. Overall, the collaboration is not about grand promises. It is about integrating hardware, running real tests and taking practical steps toward operating on the Moon.
Keep Reading
A new bet on early heart failure detection and why women’s health is at the center.
Updated
January 8, 2026 6:28 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.